News Search Results
Feb 23, 2026, 11:15 ET Connected Nation study reveals internet pricing disparities across neighborhoods, highlights need for standardized pricing
parametersCN's research revolves around two central questions: "How much do home internet prices vary by neighborhoods" and "what neighborhood-level characteristics influence pricing differences between neighborhoods?" To answer those questions, CN's researchers manually compiled
More news about: Connected Nation
Feb 23, 2026, 07:00 ET FDA Approves VUEWAY® (gadopiclenol) Solution for Injection, Intravenous Use, for Use in Neonates and Infants
54(8):475-484.6 Hao J, Pitrou C, Bourrinet P. A Comprehensive Overview of the Efficacy and Safety of Gadopiclenol: A New Contrast Agent for MRI of the CNS and Body. Invest Radiol 2024; 59(2):124-130.7 Kanal E, Maki JH, Schramm P, Marti-Bonmati L. Evolving Characteristics of Gadolinium-Based
More news about: Bracco Group
Feb 23, 2026, 03:17 ET RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
candidate RGX-111 were overwhelmingly positive while it concealed negative data on its efficacy and safety. The Company then revealed an intraventricular CNS tumor was discovered in a participant treated as part of a RGX-111 study. Based on these facts, the Company's public statements were false and materially
More news about: The Schall Law Firm
Feb 20, 2026, 04:28 ET RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
candidate RGX-111 were overwhelmingly positive while it concealed negative data on its efficacy and safety. The Company then revealed an intraventricular CNS tumor was discovered in a participant treated as part of a RGX-111 study. Based on these facts, the Company's public statements were false and materially
More news about: The Schall Law Firm
Feb 19, 2026, 20:04 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Pomerantz LLP
Feb 19, 2026, 14:47 ET RGNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Faruqi & Faruqi, LLP
Feb 19, 2026, 10:15 ET The Gross Law Firm Notifies REGENXBIO Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RGNX
press release announcing that the FDA placed a clinical hold on its investigational gene therapy RGX-111. Defendants announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. Following this news, the price of REGENXBIO's common stock declined from a
More news about: The Gross Law Firm
Feb 19, 2026, 09:05 ET Connected Nation marks quarter century of service with yearlong celebration, world record attempt for digital skills training
availability, supporting device access, and delivering hands-on digital skills training nationwide. Here's a brief look at CN's impact:150,000 individuals trained through CN's digital skills programs21 million people reached nationwide through digital empowerment initiatives150
More news about: Connected Nation
Feb 19, 2026, 08:30 ET Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping
/PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI), an AI-driven biotechnology company advancing precision therapeutics in central nervous system (CNS) disorders and oncology, as well as solutions for biodefense, today announced the issuance of U.S. Patent No. 12,369,861, titled "Methods, Systems, and
More news about: Lunai Bioworks Inc.
Feb 19, 2026, 03:30 ET Lario Therapeutics awarded $2.4m by The Michael J. Fox Foundation and Wellcome to expand neuronal calcium channel platform across CNS disorders
content:https://www.prnewswire.com/news-releases/lario-therapeutics-awarded-2-4m-by-the-michael-j-fox-foundation-and-wellcome-to-expand-neuronal-calcium-channel-platform-across-cns-disorders-302691679.htmlSOURCE
More news about: Lario Therapeutics
Feb 18, 2026, 16:43 ET RGNX Stockholder Alert: Robbins LLP Remind Investors of the Class Action Lawsuit Against REGENXBIO, Inc.
Plaintiff alleges that in truth, defendants were aware of the serious safety issues relating to the RGX-111 study including the potential for CNS neoplasm and in November 2023 abruptly decided to de-prioritize its second-most advanced clinical candidate, RGX-111, and seek "strategic alternatives"
More news about: Robbins LLP
Feb 18, 2026, 13:03 ET Belay Diagnostics Announces the Validation of Summit™ 2.0 Comprehensive Genomic Profile Assay in Cerebrospinal Fluid (CSF)
system (CNS) cancers, announced the results from the analytical and clinical validation of its Belay Summit™ 2.0 Comprehensive Genomic Profile assay. The study used both tissue biopsy-matched and definitively diagnosed cerebrospinal fluid (CSF) samples from patients with primary and metastatic CNS cancers,
More news about: Belay Diagnostics
Feb 18, 2026, 09:00 ET Shareholders that lost money on REGENXBIO Inc. (RGNX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
press release announcing that the FDA placed a clinical hold on its investigational gene therapy RGX-111. Defendants announced that an intraventricular CNS tumor was found in a participant treated in its RGX-111 Phase I/II study. Following this news, the price of REGENXBIO's common stock declined from a
More news about: Levi & Korsinsky, LLP
Feb 18, 2026, 08:00 ET Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)
for breastfeeding mothers. Data from a qEEG study in healthy volunteers demonstrated target engagement consistent with robust central nervous system (CNS) activity, with concentration- and time-dependent post-dose changes in qEEG.About Postpartum Depression and Unmet NeedsPPD is a
More news about: Lipocine Inc.
Feb 18, 2026, 07:00 ET Finding Hope for Frizzle (FRRS1L) and Apertura Gene Therapy Announce License Agreement for the Development of a Gene Therapy Using TfR1 CapX, an AAV Capsid Designed to Target the Central Nervous System
the goal of enabling efficient delivery of genetic medicines across the blood-brain barrier (BBB) and into the CNS. hTfR1 is an attractive transport target for therapeutics intended for the CNS because expression of hTfR1 is high throughout the BBB and consistent throughout life as well as across neurological
More news about: Apertura Gene Therapy
Feb 17, 2026, 14:02 ET Cindy Eckert, Women's Health Innovator, Named to TIME's 2026 TIME100 Health List of the World's Most Influential Leaders in Health
may increase the risk of hypotension and syncope.Central Nervous System (CNS) Depression (e.g., Somnolence, Sedation): Can occur with ADDYI alone and is exacerbated by other CNS depressants. The risk of CNS depression is also increased if ADDYI is taken during waking hours. Patients should
More news about: Sprout Pharmaceuticals
Feb 17, 2026, 07:00 ET Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis
will supply NKTR-0165 and will retain all rights to its programs under the collaboration."We know that TNFR2 is expressed on specific immune and CNS cells," said Dr. Hauser. "With this important research initiative, we hope to evaluate the potential neuroprotective effect associated with the agonism
More news about: Nektar Therapeutics
Feb 16, 2026, 06:45 ET Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
overall survival (OS), EFS as assessed by blinded independent central review (BICR), time to distant disease recurrence in the central nervous system (CNS) as assessed by investigator and BICR, progression-free survival on the next line of treatment (PFS2), positive predictive value (PPV) of RET
More news about: Eli Lilly and Company
Feb 13, 2026, 08:31 ET Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC
"We are deploying AI to accelerate discovery in CNS disease and biodefense," said David Weinstein, Chief Executive Officer of Lunai Bioworks. "Our platform is built to scale precision biology, reduce
More news about: Lunai Bioworks Inc.
Feb 12, 2026, 18:51 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX
therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CNS tumor) in a participant treated in its Phase I/II study." The press release also disclosed that "[t]he FDA also placed a clinical hold on RGX-121, for
More news about: Pomerantz LLP
Feb 12, 2026, 08:00 ET Apertura Gene Therapy Launches Open Aperture, a Material Transfer Agreement Program to Facilitate Non-Commercial Access to TfR1 CapX for Academic Researchers
third-party CMC vendors and contract research organizations (CROs) that are experienced with TfR1 CapX."Academic labs are doing important early work in CNS gene therapy, but progress can be slowed or even stopped when attempts to gain access to clinically relevant capsids are unsuccessful," said Dave Greenwald,
More news about: Apertura Gene Therapy
Feb 12, 2026, 07:00 ET NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
clinical-stage biopharmaceutical company advancing stem-cell-derived therapies for Type 1 Diabetes and advancing innovative therapies for central nervous system (CNS) today announced the publication of a comprehensive peer-reviewed scientific review entitled, "Mazindol Immediate-Release/Sustained-Release (IR/SR):
More news about: NewcelX Ltd.
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
September 2025, Firmonertinib showed a 68.2% ORR and 16 months mPFS in EGFR PACC-mutant NSCLC (Phase Ib FURTHER trial). It also demonstrated strong CNS activity, including complete responses in brain metastases.In September 2025, Sunvozertinib achieved an ORR >80% and 100% disease
More news about: DelveInsight Business Research, LLP
Feb 11, 2026, 16:01 ET Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
a landmark narrative review on FDA-approved vesicular monoamine transporter 2 (VMAT2) inhibitors demonstrating the unique profile of INGREZZA in CNS Spectrums. The review highlighted the distinct profile of INGREZZA, including selective VMAT2 targeting, simplified dosing without required titration
More news about: Neurocrine Biosciences, Inc.
Feb 10, 2026, 10:00 ET SkyGrid and Port San Antonio Partner to Enable Advanced Air Mobility at a Joint-Use Airfield
awareness Advanced Air Mobility service provisions Airport and vertiport operational concepts Communication, navigation, and surveillance (CNS) systems and cyber-resilient infrastructure Ground system certification and operational approvals The collaboration will also explore
More news about: SkyGrid